NASDAQ: VIR · Biotechnology

Vir Biotechnology (VIR) fair value and price range

As of 14 Nov 2026, Faircurve's model values Vir Biotechnology (VIR) at $9.51 a share. The stock last closed at $9.58, which puts the model's fair value 0.7% below the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

Revalued . Price is the close of 16 Nov 2026. Vir Biotechnology, Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$9.51midpoint of 2,000 simulations
Last close$9.58NASDAQ: VIR
Gap to fair value-0.7%fair value against price
Model verdictLow evidence gradeevidence grade: Low

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $11.47 to $9.51 (-17.1%). The multiple the model anchors on moved, lowering the fair value: most of the move.

What the model makes of itThe price of $9.58 is 0.7% above it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

What's nextNext report on 22 Feb 2027. Options prices imply a move of about 21% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give VIR?

The calibrated range for VIR over 63 trading days is $7.53 to $12.34. It sits around the last close, and its width comes from the volatility that VIR's own options imply (73% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $6.24 to $14.13. In 46% of the simulations the fair value came out above the price the model ran on.

$3.95$26.29
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $9.51. Dashed line: the last close, $9.58.

Faircurve Insights · 14 Nov 2026

Vir Biotechnology, Inc. operates as an immunology company with commercialized products. Its sector is Healthcare, Biotechnology.

Faircurve's model gave a fair value of $9.51 a share for Vir Biotechnology on 14 Nov 2026. This is the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $11.47, so the fair value moved -17.1%. The multiple the model anchors on moved, lowering the fair value: most of the move. The calibrated range over 63 trading days is $7.53 to $12.34, based on the volatility the stock's own options imply. Ranges built this way held the price 60% of the time at this horizon, across 8,038 past valuations refreshed on 14 Nov 2026. The model grades the evidence behind this valuation as low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.

The model's overall quality score is 52 out of 100, a composite of six quality factors scored against comparable companies. Profitability stands out at 72, with ROIC at -27.5% against a peer median of -40.4%. Balance sheet scores 64, with net debt to EBITDA at 0.66x. Stability scores 0, with five-year EBITDA margin downside volatility at 232.2 pts against a peer median of 40.3 pts. The model compares the company with Fortrea Holdings Inc. (FTRE), Vericel Corporation (VCEL) and ADMA Biologics, Inc. (ADMA), each of which has a fair value of its own on the site.

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does VIR report earnings, and how has the stock reacted?

Vir Biotechnology's next earnings report is scheduled for 22 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 17.0% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. VIR's 30 day implied volatility works out to about 21.1% over one month.

Around its last 3 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across VIR's last 8 reports, ignoring direction, was 9.1%.

0%5%10%15%20%no quote7.4%6 May '26no quote4.4%5 Aug '2615.8%1.8%4 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

Earlier reports are left out: the options record before 24 Feb 2026 is not comparable.

What the options market has priced for a month's move in VIR

15%20%25%30%4 Nov '26 report5 Aug '26 report6 May '26 report21% at 16 Nov '2627 Feb '2616 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 20% on 27 Feb 2026, reached 27% on 6 Nov 2026 and reads 21% on 16 Nov 2026. The marks are report dates.

How does VIR score on business quality?

Vir Biotechnology's overall quality score is 52 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.72-27.5%ROIC-40.4%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).43
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.52-7.6%Revenue growth, trailing64.7%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.500.0%Net buybacks / market value0.0%
Balance sheetNet debt to EBITDA and interest coverage.640.66xNet debt / EBITDA
StabilityDownside volatility of the EBITDA margin over the last five years.0232.2 ptsEBITDA margin downside volatility, 5y40.3 pts

How does VIR compare with similar companies?

The companies in biotechnology closest to Vir Biotechnology in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
SRPT Sarepta Therapeutics, Inc.$15.13$19.51+28.9%Low evidence grade
FTRE Fortrea Holdings Inc.$19.79$24.79+25.3%Undervalued
HRMY Harmony Biosciences Holdings, Inc.$32.96$33.93+2.9%Low evidence grade
INVA Innoviva, Inc.$18.49$19.11+3.4%Low evidence grade
RCUS Arcus Biosciences, Inc.$16.86$16.32-3.2%Low evidence grade
XNCR Xencor, Inc.$35.40$35.72+0.9%Low evidence grade
VCEL Vericel Corporation$57.48$65.96+14.8%Fairly valued
ADMA ADMA Biologics, Inc.$13.47$15.96+18.5%Undervalued

What the comparable companies' multiples alone would give for VIR, the peer-implied price, is $6.28 a share on this run. The fair value weighs that against the company's own multiple.

All biotechnology stocks ranked by gap to fair value

Vir Biotechnology at a glance

Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases.

Market value
$1.7B
Sector
Healthcare
Industry
Biotechnology
Revenue expected, next twelve months
$104M
Consensus revenue growth, next fiscal year
+382.0%
Analysts with estimates
5
Beta to the US market
1.87
First valued by Faircurve
11 Jul 2026

How the fair value is worked out: the model prices Vir Biotechnology on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for VIR was $11.47. As of 14 Nov 2026 it is $9.51, a change of -17.1%. The multiple the model anchors on moved, lowering the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Vir Biotechnology's valuation

Is Vir Biotechnology stock undervalued or overvalued?

Faircurve's model puts VIR's fair value at $9.51 a share against a last close of $9.58, as of 14 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

What is VIR's fair value?

$9.51 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $6.24 to $14.13.

What price range does the model give VIR?

$7.53 to $12.34 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Vir Biotechnology report earnings next?

The next report is scheduled for 22 Feb 2027. Companies can move their dates.

How much has VIR moved on past earnings reports?

Across its last 8 reports the median two session move was 9.1%, ignoring direction. The largest was +25.5% around the report of 23 Feb 2026.

How confident is the model in this valuation?

The model's evidence grade for VIR is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on VIR

The model holds no idea open on VIR today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on VIR with their outcomes. A free account is enough.

Keep reading